Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of AMT-060 gene therapy in adult haemophilia B
NL-OMON54158Phase 2Active, not recruiting
- Sponsor
- CSL Behring
- Start
- Mar 2021
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoints: Long-term safety after dosing of AAV5-hFIX, Adverse events related to prior AAV5-hFIX administration and 3 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON54158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54158.